Liothyronine prescribing in England: costs versus need

Lancet. 2023 Dec 2;402(10417):2074-2075. doi: 10.1016/S0140-6736(23)01792-0. Epub 2023 Nov 15.

Authors

Adrian Heald¹, Mike Stedman², Buchi Okosieme³, Lakdasa Premawardhana³, Peter Taylor³, Colin Dayan³

Affiliations

¹ The School of Medicine and Manchester Academic Health Sciences Centre, University of Manchester, Manchester M14 4PX, UK; Department of Diabetes and Endocrinology, Salford Royal NHS Foundation Trust, Salford, UK. Electronic address: adrian.heald@manchester.ac.uk.
² RES Consortium, Andover, UK.
³ Thyroid Research Group, Systems Immunity Research Institute, Cardiff University School of Medicine, Cardiff, UK.

PMID: 37979592
DOI: 10.1016/S0140-6736(23)01792-0

No abstract available

Publication types

Letter

MeSH terms

Costs and Cost Analysis
Drug Costs
Drug Prescriptions*
England
Humans
Practice Patterns, Physicians'
Triiodothyronine*

Substances

Triiodothyronine